Therapeutic antibodies for treatment and prophylaxis of transmittable viral diseases
The invention provides methods and compositions for the treatment and prevention of a transmittable disease in a subject, such as avians and mammals. The methods and compositions of the invention specifically make use of avian antibodies to the disease to be treated or prevented. Administration of such avian antibodies to a subject has been shown effective for reducing mortality in a population of subjects that are infected, or become infected, with the disease. The invention also provides kits useful for detecting the presence of transmittable diseases in subjects.
1. A method of treating a mammal infected with a virus in the Flaviviridae family comprising administering to the infected mammal a composition comprising polyclonal goose antibodies against a virus in the Flaviviridae family, wherein the mammal has not been de-sensitized to goose antibodies prior to said step of administering the composition comprising the polyclonal goose antibodies against the virus in the Flaviviridae family.
2. The method of claim 1 , wherein the mammal is selected from the group consisting of goats, horses, rabbits, rats, mice, pigs, and humans.
3. The method of claim 1 , wherein the virus infecting the mammal is a flavivirus.
4. The method of claim 1 , wherein the flavivirus is selected from the group consisting of Gadgets Gully virus, Kadam virus, Kyasanur Forest disease virus, Langat virus, Omsk hemorrhagic fever virus, Powassan virus, Royal Farm virus, Tick-borne encephalitis virus, Louping ill virus, Meaban virus, Saumarez Reef virus, Tyuleniy virus, Aroa virus, Dengue virus, Kedougou virus, Cacipacore virus, Koutango virus, Japanese encephalitis virus, Murray Valley encephalitis virus, St. Louis encephalitis virus, Usutu virus, West Nile virus, Yaounde virus, Kokovera virus, Bagaza virus, Ilheus virus, Israel turkey meningoencephalomyelitis virus, Ntaya virus, Tembusu virus, Zika virus, Banzi virus, Bouboui virus, Edge Hill virus, Jugra virus, Saboya virus, Sepik virus, Uganda S virus, Wesselsbron virus, Yellow fever virus, Entebbe bat virus, Yokose virus, Apoi virus, Cowbone Ridge virus, Jutiapa virus, Modoc virus, Sal Vieja virus, San Perlita virus, Bukalasa bat virus, Carey Island virus, Dakar bat virus, Montana myotis leukoencephalitis virus, Phnom Penh bat virus, and Rio Bravo virus.
5. The method of claim 1 , wherein the composition comprises polyclonal goose antibodies against a virus in the flavivirus genus.
6. The method of claim 5 , wherein the virus is selected from the group consisting of Gadgets Gully virus, Kadam virus, Kyasanur Forest disease virus, Langat virus, Omsk hemorrhagic fever virus, Powassan virus, Royal Farm virus, Tick-borne encephalitis virus, Louping ill virus, Meaban virus, Saumarez Reef virus, Tyuleniy virus, Aroa virus, Dengue virus, Kedougou virus, Cacipacore virus, Koutango virus, Japanese encephalitis virus, Murray Valley encephalitis virus, St. Louis encephalitis virus, Usutu virus, West Nile virus, Yaounde virus, Kokovera virus, Bagaza virus, Ilheus virus, Israel turkey meningoencephalomyelitis virus, Ntaya virus, Tembusu virus, Zika virus, Banzi virus, Bouboui virus, Edge Hill virus, Jugra virus, Saboya virus, Sepik virus, Uganda S virus, Wesselsbron virus, Yellow fever virus, Entebbe bat virus, Yokose virus, Apoi virus, Cowbone Ridge virus, Jutiapa virus, Modoc virus, Sal Vieja virus, San Perlita virus, Bukalasa bat virus, Carey Island virus, Dakar bat virus, Montana myotis leukoencephalitis virus, Phnom Penh bat virus, and Rio Bravo virus.
7. The method of claim 1 , wherein the virus that the polyclonal goose antibodies are against is the same virus infecting the mammal.
8. The method of claim 1 , wherein the virus that the polyclonal goose antibodies are against is different from the virus infecting the mammal.
9. The method of claim 1 , wherein said treating comprises preventing or limiting one or more symptoms associated with infection by the virus.
10. The method of claim 1 , wherein the composition is derived from a serum that exhibits a neutralization titer of at least about 1:200 when evaluated according to a plaque reduction test.
11. The method of claim 10 , wherein the serum exhibits a neutralization titer of at least about 1:500 when evaluated according to a plaque reduction test.
12. The method of claim 10 , wherein the serum exhibits a neutralization titer of at least about 1:1000 when evaluated according to a plaque reduction test.
13. The method of claim 1 , wherein said administering comprises a route of administration selected from the group consisting of injection, inhalation, oral administration, and combinations thereof.